



Patients name

Address

Phone no.

E-mail

DOB

NHI

ACC

Insurance

Yes No

Provider

Referring Practitioner

Name

NZNM provider #

Phone no.

Date

Please send all therapy related correspondence to

Signature

Diagnosis

Reason for referral

Prostate Cancer related history and previous treatment

Other Medical History

Current Medication and Doses

Allergies

ECOG

Current Symptoms

Most recent PSMA PET-CT Imaging:

Date

Site

Most recent FDG PET-CT Imaging:

Date

Site

Kindly attach most recent blood results:

2 latest consecutive PSA Levels

FBC

U&E

LFT

Eligibility criteria for PSMA Therapy

¹⁷⁷Lu-PSMA will be administered following assessment of suitability by a Nuclear Medicine Specialist and managed in close collaboration with the patient's medical oncologist. The following criteria should be met in order to be suitable for ¹⁷⁷Lu-PSMA.

Inclusion criteria

1. Diagnosis of mCRPC
2. Progression or intolerance on a novel anti-androgen therapy
3. Prior therapy with at least one taxane cytotoxic (these agents may have been received upfront for metastatic hormone-sensitive prostate cancer) or the patient is symptomatic* and assessed as unfit for chemotherapy
4. Evidence of disease progression defined by one of:
 - a. Rising PSA (at least 2 consecutive rises greater than 1 week apart) (PCWG3 criteria)
 - b. Radiographic progression on CT scan, bone scan or PSMA PET/CT
 - c. Clinical progression defined by cancer-related pain requiring regular analgesia and/or radiotherapy for site of cancer-related pain within the previous 12 weeks
5. Ongoing treatment with androgen deprivation therapy (ADT) unless history of bilateral orchidectomy
6. Adequate haematological, renal and hepatic functions as defined by
 - a. Absolute neutrophil count $>1.5 \times 10^9 /L$
 - b. Platelet count $>100 \times 10^9 /L$
 - c. Haemoglobin $\geq 90 \text{ g/L}$ (transfusion permissible)
 - d. Albumin $\geq 25 \text{ g/L}$ (unless long-standing owing to chronic condition)
 - e. eGFR $\geq 30 \text{ ml/min}$
- 7 Performance status of 0-3 on the ECOG Performance Scale
8. Life expectancy greater than 6 months
9. PSMA and FDG PET/CT within 2 months of commencing treatment

Exclusion criteria for PSMA Therapy

1. Symptomatic cord compression, or clinical, or imaging findings concerning for impending cord compression